Compounded Aseptic Medicines
A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1M-£14M
- Sector
- HEALTH
- Published
- 24 Feb 2025
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
1 buyer
- NHS National Services Scotland NSS Edinburgh
3 suppliers
- Baxter Healthcare Berkshire
- Qualasept Corsham
- Ith Pharma London
Description
This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland.
Lot Division
| 1 | Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Atezolizumab Cetuximab Doxorubicin Epirubicin Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab Pembrolizumab Pertuzumab The Authority intends to awarded all presentations within this Lot to a single supplier. |
| 2 | Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Cyclophosphamide Fluorouracil Irinotecan Methotrexate Rituximab (Mabthera®), (Rixathon®), (Truxima®) The Authority intends to awarded all presentations within this Lot to a single supplier |
| 3 | Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Bortezomib Carboplatin Cisplatin Docetaxel Gemcitabine Oxaliplatin Trastuzumab (Herceptin®), (Herzuma®) Vincristine The Authority intends to awarded all presentations within this Lot to a single supplier. |
| 4 | Compounded Aseptic Medicines - All Other Presentations Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, The molecules included in this Lot are, Bevacizumab Cytarabine Infliximab (Zessly®) Insulin Methotrexate Natalizumab Nivolumab Paclitaxel Pemetrexed Tocilizumab Trastuzumab (Kanjinti®), (Ontruzant®) Trastuzumab Subcutaneous Vedolizumab Each product line will be treated as an individual Lot and awarded as an unranked multi-supplier framework. |
Award Detail
| 1 | Baxter Healthcare (Berkshire)
|
| 2 | Qualasept (Corsham)
|
| 3 | Baxter Healthcare (Berkshire)
|
| 4 | Baxter Healthcare (Berkshire)
|
| 5 | Qualasept (Corsham)
|
| 6 | Ith Pharma (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
Legal Justification
This VEAT notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value(s) of the Framework Agreement referred to in Section V.2.4 (comprising three (4) Lots) cover(s) the twelve (12) month duration of the proposed modification period of the Framework Agreement. NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=790498. (SC Ref:790498)
Reference
- ocds-h6vhtk-04e7a2
- FTS 007093-2025